META 2i
Alternative Names: META-02; META-2iLatest Information Update: 19 Dec 2023
At a glance
- Originator META Pharmaceuticals
- Class Small molecules
- Mechanism of Action Immunomodulators; Metabolism-modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Metabolic disorders
Most Recent Events
- 18 Dec 2023 Early research in Metabolic disorders in China (unspecified route) prior to December 2023 (META Pharmaceuticals pipeline, December 2023)
- 19 Jun 2023 Early research in Autoimmune disorders in China (unspecified route) prior to June 2023 (META Pharmaceuticals pipeline, June 2023)
- 13 Jun 2023 META Pharmaceuticals enters into an agreement with Jingtai Technology to use new biological mechanisms and new solutions